http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 19 Aug 2026 04:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Results+from+2026+Annual+General+Meeting/26946361.html <p>VANCOUVER, British Columbia, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce the results of voting at its 2026 annual general meeting of shareholders held on August 18, 2026, in Toronto, Ontario (the “Meeting”).</p> <p>All five members of the Company’s board of directors named as nominees in its management information circular dated July 14, 2026 (the “Circular”) were elected as directors: Kim Oishi, Frank Holler, Dr. David Kideckel, Yevgeniy Meshcherekov and Dr. Petra Hamerlik.</p> <p>In addition, at http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Results+from+2026+Annual+General+Meeting/26946361.html Wed, 19 Aug 2026 04:00:00 -0400 7JO0 O.48931914 RKV http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Results+from+2026+Annual+General+Meeting/26946361.html <p>VANCOUVER, British Columbia, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce the results of voting at its 2026 annual general meeting of shareholders held on August 18, 2026, in Toronto, Ontario (the “Meeting”).</p> <p>All five members of the Company’s board of directors named as nominees in its management information circular dated July 14, 2026 (the “Circular”) were elected as directors: Kim Oishi, Frank Holler, Dr. David Kideckel, Yevgeniy Meshcherekov and Dr. Petra Hamerlik.</p> <p>In addition, at http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Results+from+2026+Annual+General+Meeting/26946361.html Wed, 19 Aug 2026 04:00:00 -0400 7JO0 O.48931914 RKV http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Results+from+2026+Annual+General+Meeting/26946361.html <p>VANCOUVER, British Columbia, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce the results of voting at its 2026 annual general meeting of shareholders held on August 18, 2026, in Toronto, Ontario (the “Meeting”).</p> <p>All five members of the Company’s board of directors named as nominees in its management information circular dated July 14, 2026 (the “Circular”) were elected as directors: Kim Oishi, Frank Holler, Dr. David Kideckel, Yevgeniy Meshcherekov and Dr. Petra Hamerlik.</p> <p>In addition, at http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Results+from+2026+Annual+General+Meeting/26946361.html Wed, 19 Aug 2026 04:00:00 -0400 7JO0 O.48931914 RKV http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Results+from+2026+Annual+General+Meeting/26946361.html <p>VANCOUVER, British Columbia, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce the results of voting at its 2026 annual general meeting of shareholders held on August 18, 2026, in Toronto, Ontario (the “Meeting”).</p> <p>All five members of the Company’s board of directors named as nominees in its management information circular dated July 14, 2026 (the “Circular”) were elected as directors: Kim Oishi, Frank Holler, Dr. David Kideckel, Yevgeniy Meshcherekov and Dr. Petra Hamerlik.</p> <p>In addition, at http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Results+from+2026+Annual+General+Meeting/26946361.html Wed, 19 Aug 2026 04:00:00 -0400 7JO0 O.48931914 RKV http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Results+from+2026+Annual+General+Meeting/26946361.html <p>VANCOUVER, British Columbia, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce the results of voting at its 2026 annual general meeting of shareholders held on August 18, 2026, in Toronto, Ontario (the “Meeting”).</p> <p>All five members of the Company’s board of directors named as nominees in its management information circular dated July 14, 2026 (the “Circular”) were elected as directors: Kim Oishi, Frank Holler, Dr. David Kideckel, Yevgeniy Meshcherekov and Dr. Petra Hamerlik.</p> <p>In addition, at http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Results+from+2026+Annual+General+Meeting/26946361.html Wed, 19 Aug 2026 04:00:00 -0400 7JO0 O.48931914 RKV http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Results+from+2026+Annual+General+Meeting/26946361.html <p>VANCOUVER, British Columbia, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce the results of voting at its 2026 annual general meeting of shareholders held on August 18, 2026, in Toronto, Ontario (the “Meeting”).</p> <p>All five members of the Company’s board of directors named as nominees in its management information circular dated July 14, 2026 (the “Circular”) were elected as directors: Kim Oishi, Frank Holler, Dr. David Kideckel, Yevgeniy Meshcherekov and Dr. Petra Hamerlik.</p> <p>In addition, at http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Results+from+2026+Annual+General+Meeting/26946361.html Wed, 19 Aug 2026 04:00:00 -0400 7JO0 O.48931914 RKV http://www.streetinsider.com/Equity+Offerings/Rakovina+Therapeutics+closes+first+tranche%2C+upsizes+private+placement/26907866.html <p>Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) has closed the first tranche of a non-brokered private placement, raising $1,394,000 through the issuance of 13,940,000 units at $0.10 per unit, according to a press release.</p> <p>Each unit consists of one common share and one-half of one common share purchase warrant. Each whole warrant allows the holder to acquire one additional share at $0.20 for 24 months from the date of issue.</p> <p>The company also announced it is increasing the total size of the offering from $1,500,000 to up to $2,000,000 and extending the closing deadline by 30 days to September 10, 2026.</p> <p>In connection http://www.streetinsider.com/Equity+Offerings/Rakovina+Therapeutics+closes+first+tranche%2C+upsizes+private+placement/26907866.html Wed, 12 Aug 2026 04:00:20 -0400 7JO0 A.36078215 O.02555813 O.48931914 RKV http://www.streetinsider.com/Equity+Offerings/Rakovina+Therapeutics+closes+first+tranche%2C+upsizes+private+placement/26907866.html <p>Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) has closed the first tranche of a non-brokered private placement, raising $1,394,000 through the issuance of 13,940,000 units at $0.10 per unit, according to a press release.</p> <p>Each unit consists of one common share and one-half of one common share purchase warrant. Each whole warrant allows the holder to acquire one additional share at $0.20 for 24 months from the date of issue.</p> <p>The company also announced it is increasing the total size of the offering from $1,500,000 to up to $2,000,000 and extending the closing deadline by 30 days to September 10, 2026.</p> <p>In connection http://www.streetinsider.com/Equity+Offerings/Rakovina+Therapeutics+closes+first+tranche%2C+upsizes+private+placement/26907866.html Wed, 12 Aug 2026 04:00:20 -0400 7JO0 A.36078215 O.02555813 O.48931914 RKV http://www.streetinsider.com/Equity+Offerings/Rakovina+Therapeutics+closes+first+tranche%2C+upsizes+private+placement/26907866.html <p>Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) has closed the first tranche of a non-brokered private placement, raising $1,394,000 through the issuance of 13,940,000 units at $0.10 per unit, according to a press release.</p> <p>Each unit consists of one common share and one-half of one common share purchase warrant. Each whole warrant allows the holder to acquire one additional share at $0.20 for 24 months from the date of issue.</p> <p>The company also announced it is increasing the total size of the offering from $1,500,000 to up to $2,000,000 and extending the closing deadline by 30 days to September 10, 2026.</p> <p>In connection http://www.streetinsider.com/Equity+Offerings/Rakovina+Therapeutics+closes+first+tranche%2C+upsizes+private+placement/26907866.html Wed, 12 Aug 2026 04:00:20 -0400 7JO0 A.36078215 O.02555813 O.48931914 RKV http://www.streetinsider.com/Equity+Offerings/Rakovina+Therapeutics+closes+first+tranche%2C+upsizes+private+placement/26907866.html <p>Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) has closed the first tranche of a non-brokered private placement, raising $1,394,000 through the issuance of 13,940,000 units at $0.10 per unit, according to a press release.</p> <p>Each unit consists of one common share and one-half of one common share purchase warrant. Each whole warrant allows the holder to acquire one additional share at $0.20 for 24 months from the date of issue.</p> <p>The company also announced it is increasing the total size of the offering from $1,500,000 to up to $2,000,000 and extending the closing deadline by 30 days to September 10, 2026.</p> <p>In connection http://www.streetinsider.com/Equity+Offerings/Rakovina+Therapeutics+closes+first+tranche%2C+upsizes+private+placement/26907866.html Wed, 12 Aug 2026 04:00:20 -0400 7JO0 A.36078215 O.02555813 O.48931914 RKV http://www.streetinsider.com/Equity+Offerings/Rakovina+Therapeutics+closes+first+tranche%2C+upsizes+private+placement/26907866.html <p>Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) has closed the first tranche of a non-brokered private placement, raising $1,394,000 through the issuance of 13,940,000 units at $0.10 per unit, according to a press release.</p> <p>Each unit consists of one common share and one-half of one common share purchase warrant. Each whole warrant allows the holder to acquire one additional share at $0.20 for 24 months from the date of issue.</p> <p>The company also announced it is increasing the total size of the offering from $1,500,000 to up to $2,000,000 and extending the closing deadline by 30 days to September 10, 2026.</p> <p>In connection http://www.streetinsider.com/Equity+Offerings/Rakovina+Therapeutics+closes+first+tranche%2C+upsizes+private+placement/26907866.html Wed, 12 Aug 2026 04:00:20 -0400 7JO0 A.36078215 O.02555813 O.48931914 RKV http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Closing+of+First+Tranche%2C+Upsize+and+Extension+of+Non-Brokered+Private+Placement/26907864.html <p>VANCOUVER, British Columbia, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that it has closed the first tranche (the “First Tranche”) of its previously announced non-brokered private placement (the “Offering”), initially announced on July 15, 2026. The First Tranche consisted of 13,940,000 units (“Units”) at a price of $0.10 per Unit for aggregate gross proceeds of $1,394,000. The Company is also pleased to announce that, due to strong investor demand, it is increasing the size of the Offering http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Closing+of+First+Tranche%2C+Upsize+and+Extension+of+Non-Brokered+Private+Placement/26907864.html Wed, 12 Aug 2026 04:00:00 -0400 7JO0 A.36078215 O.02555813 O.48931914 RKV http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Closing+of+First+Tranche%2C+Upsize+and+Extension+of+Non-Brokered+Private+Placement/26907864.html <p>VANCOUVER, British Columbia, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that it has closed the first tranche (the “First Tranche”) of its previously announced non-brokered private placement (the “Offering”), initially announced on July 15, 2026. The First Tranche consisted of 13,940,000 units (“Units”) at a price of $0.10 per Unit for aggregate gross proceeds of $1,394,000. The Company is also pleased to announce that, due to strong investor demand, it is increasing the size of the Offering http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Closing+of+First+Tranche%2C+Upsize+and+Extension+of+Non-Brokered+Private+Placement/26907864.html Wed, 12 Aug 2026 04:00:00 -0400 7JO0 A.36078215 O.02555813 O.48931914 RKV http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Closing+of+First+Tranche%2C+Upsize+and+Extension+of+Non-Brokered+Private+Placement/26907864.html <p>VANCOUVER, British Columbia, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that it has closed the first tranche (the “First Tranche”) of its previously announced non-brokered private placement (the “Offering”), initially announced on July 15, 2026. The First Tranche consisted of 13,940,000 units (“Units”) at a price of $0.10 per Unit for aggregate gross proceeds of $1,394,000. The Company is also pleased to announce that, due to strong investor demand, it is increasing the size of the Offering http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Closing+of+First+Tranche%2C+Upsize+and+Extension+of+Non-Brokered+Private+Placement/26907864.html Wed, 12 Aug 2026 04:00:00 -0400 7JO0 A.36078215 O.02555813 O.48931914 RKV http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Closing+of+First+Tranche%2C+Upsize+and+Extension+of+Non-Brokered+Private+Placement/26907864.html <p>VANCOUVER, British Columbia, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that it has closed the first tranche (the “First Tranche”) of its previously announced non-brokered private placement (the “Offering”), initially announced on July 15, 2026. The First Tranche consisted of 13,940,000 units (“Units”) at a price of $0.10 per Unit for aggregate gross proceeds of $1,394,000. The Company is also pleased to announce that, due to strong investor demand, it is increasing the size of the Offering http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Closing+of+First+Tranche%2C+Upsize+and+Extension+of+Non-Brokered+Private+Placement/26907864.html Wed, 12 Aug 2026 04:00:00 -0400 7JO0 A.36078215 O.02555813 O.48931914 RKV http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Closing+of+First+Tranche%2C+Upsize+and+Extension+of+Non-Brokered+Private+Placement/26907864.html <p>VANCOUVER, British Columbia, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that it has closed the first tranche (the “First Tranche”) of its previously announced non-brokered private placement (the “Offering”), initially announced on July 15, 2026. The First Tranche consisted of 13,940,000 units (“Units”) at a price of $0.10 per Unit for aggregate gross proceeds of $1,394,000. The Company is also pleased to announce that, due to strong investor demand, it is increasing the size of the Offering http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Closing+of+First+Tranche%2C+Upsize+and+Extension+of+Non-Brokered+Private+Placement/26907864.html Wed, 12 Aug 2026 04:00:00 -0400 7JO0 A.36078215 O.02555813 O.48931914 RKV http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Closing+of+First+Tranche%2C+Upsize+and+Extension+of+Non-Brokered+Private+Placement/26907864.html <p>VANCOUVER, British Columbia, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that it has closed the first tranche (the “First Tranche”) of its previously announced non-brokered private placement (the “Offering”), initially announced on July 15, 2026. The First Tranche consisted of 13,940,000 units (“Units”) at a price of $0.10 per Unit for aggregate gross proceeds of $1,394,000. The Company is also pleased to announce that, due to strong investor demand, it is increasing the size of the Offering http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Closing+of+First+Tranche%2C+Upsize+and+Extension+of+Non-Brokered+Private+Placement/26907864.html Wed, 12 Aug 2026 04:00:00 -0400 7JO0 A.36078215 O.02555813 O.48931914 RKV http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Closing+of+First+Tranche%2C+Upsize+and+Extension+of+Non-Brokered+Private+Placement/26907864.html <p>VANCOUVER, British Columbia, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that it has closed the first tranche (the “First Tranche”) of its previously announced non-brokered private placement (the “Offering”), initially announced on July 15, 2026. The First Tranche consisted of 13,940,000 units (“Units”) at a price of $0.10 per Unit for aggregate gross proceeds of $1,394,000. The Company is also pleased to announce that, due to strong investor demand, it is increasing the size of the Offering http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Closing+of+First+Tranche%2C+Upsize+and+Extension+of+Non-Brokered+Private+Placement/26907864.html Wed, 12 Aug 2026 04:00:00 -0400 7JO0 A.36078215 O.02555813 O.48931914 RKV http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Closing+of+First+Tranche%2C+Upsize+and+Extension+of+Non-Brokered+Private+Placement/26907864.html <p>VANCOUVER, British Columbia, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that it has closed the first tranche (the “First Tranche”) of its previously announced non-brokered private placement (the “Offering”), initially announced on July 15, 2026. The First Tranche consisted of 13,940,000 units (“Units”) at a price of $0.10 per Unit for aggregate gross proceeds of $1,394,000. The Company is also pleased to announce that, due to strong investor demand, it is increasing the size of the Offering http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Closing+of+First+Tranche%2C+Upsize+and+Extension+of+Non-Brokered+Private+Placement/26907864.html Wed, 12 Aug 2026 04:00:00 -0400 7JO0 A.36078215 O.02555813 O.48931914 RKV http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Closing+of+First+Tranche%2C+Upsize+and+Extension+of+Non-Brokered+Private+Placement/26907864.html <p>VANCOUVER, British Columbia, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that it has closed the first tranche (the “First Tranche”) of its previously announced non-brokered private placement (the “Offering”), initially announced on July 15, 2026. The First Tranche consisted of 13,940,000 units (“Units”) at a price of $0.10 per Unit for aggregate gross proceeds of $1,394,000. The Company is also pleased to announce that, due to strong investor demand, it is increasing the size of the Offering http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Closing+of+First+Tranche%2C+Upsize+and+Extension+of+Non-Brokered+Private+Placement/26907864.html Wed, 12 Aug 2026 04:00:00 -0400 7JO0 A.36078215 O.02555813 O.48931914 RKV http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Closing+of+First+Tranche%2C+Upsize+and+Extension+of+Non-Brokered+Private+Placement/26907864.html <p>VANCOUVER, British Columbia, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that it has closed the first tranche (the “First Tranche”) of its previously announced non-brokered private placement (the “Offering”), initially announced on July 15, 2026. The First Tranche consisted of 13,940,000 units (“Units”) at a price of $0.10 per Unit for aggregate gross proceeds of $1,394,000. The Company is also pleased to announce that, due to strong investor demand, it is increasing the size of the Offering http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Closing+of+First+Tranche%2C+Upsize+and+Extension+of+Non-Brokered+Private+Placement/26907864.html Wed, 12 Aug 2026 04:00:00 -0400 7JO0 A.36078215 O.02555813 O.48931914 RKV http://www.streetinsider.com/Equity+Offerings/Rakovina+Therapeutics+plans+%241.5M+private+placement/26774558.html <p>Rakovina Therapeutics Inc. (TSX-V: RKV, FSE: 7JO0) announced a non-brokered private placement of up to $1.5 million, according to a press release from the Vancouver-based biopharmaceutical company.</p> <p>The offering consists of up to 15 million units priced at $0.10 per unit. Each unit includes one common share and one-half of one common share purchase warrant. Each whole warrant allows the holder to purchase one additional common share at $0.20, exercisable for 24 months from issuance.</p> <p>The company stated that proceeds will primarily fund in vivo ADME and efficacy testing for its kt-5000AI dual ATR/mTOR inhibitor program and AI-driven lead optimization through its http://www.streetinsider.com/Equity+Offerings/Rakovina+Therapeutics+plans+%241.5M+private+placement/26774558.html Wed, 15 Jul 2026 16:32:50 -0400 7JO0 O.48931914 RKV http://www.streetinsider.com/Equity+Offerings/Rakovina+Therapeutics+plans+%241.5M+private+placement/26774558.html <p>Rakovina Therapeutics Inc. (TSX-V: RKV, FSE: 7JO0) announced a non-brokered private placement of up to $1.5 million, according to a press release from the Vancouver-based biopharmaceutical company.</p> <p>The offering consists of up to 15 million units priced at $0.10 per unit. Each unit includes one common share and one-half of one common share purchase warrant. Each whole warrant allows the holder to purchase one additional common share at $0.20, exercisable for 24 months from issuance.</p> <p>The company stated that proceeds will primarily fund in vivo ADME and efficacy testing for its kt-5000AI dual ATR/mTOR inhibitor program and AI-driven lead optimization through its http://www.streetinsider.com/Equity+Offerings/Rakovina+Therapeutics+plans+%241.5M+private+placement/26774558.html Wed, 15 Jul 2026 16:32:50 -0400 7JO0 O.48931914 RKV http://www.streetinsider.com/Equity+Offerings/Rakovina+Therapeutics+plans+%241.5M+private+placement/26774558.html <p>Rakovina Therapeutics Inc. (TSX-V: RKV, FSE: 7JO0) announced a non-brokered private placement of up to $1.5 million, according to a press release from the Vancouver-based biopharmaceutical company.</p> <p>The offering consists of up to 15 million units priced at $0.10 per unit. Each unit includes one common share and one-half of one common share purchase warrant. Each whole warrant allows the holder to purchase one additional common share at $0.20, exercisable for 24 months from issuance.</p> <p>The company stated that proceeds will primarily fund in vivo ADME and efficacy testing for its kt-5000AI dual ATR/mTOR inhibitor program and AI-driven lead optimization through its http://www.streetinsider.com/Equity+Offerings/Rakovina+Therapeutics+plans+%241.5M+private+placement/26774558.html Wed, 15 Jul 2026 16:32:50 -0400 7JO0 O.48931914 RKV http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+%241.5+Million+Private+Placement/26774555.html <p align="left">VANCOUVER, British Columbia, July 15, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV)( FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, today announces a non-brokered private placement offering (the “Offering”) of up to $1.5 million.</p> <p align="justify">Pursuant to the Offering, Rakovina will issue up to 15 million equity units (“Units”) at an offering price of $0.10 per Unit, with each Unit consisting of one common share and one-half of one common share purchase warrant (a “Warrant”). Each whole Warrant will entitle the holder to acquire one additional common http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+%241.5+Million+Private+Placement/26774555.html Wed, 15 Jul 2026 16:32:00 -0400 7JO0 O.48931914 RKV